
Angina Pectoris- Pipeline Insight, 2025
Description
DelveInsight’s, “Angina Pectoris- Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angina Pectoris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Angina Pectoris: Overview
Angina is chest discomfort or pain caused by reduced blood flow to the heart muscle. Treatment primarily involves relieving symptoms by resting and using angina medications, as well as lifestyle changes to improve overall heart health. Angina, which is also known as angina pectoris, occurs when the flow of blood through the coronary arteries to the heart muscle is insufficient to meet the heart’s oxygen demands, such as during physical activity.Coronary heart disease is the most common cause of reduced blood flow to the heart in people with angina. Coronary heart disease is the build-up of fatty deposits on the inside of the coronary arteries causing them to become narrow and restricting the amount of blood flowing to the heart muscle. Angina differs from a heart attack because the reduction in blood flow to the heart muscle is only temporary and does not result in damage to the heart muscle. During a heart attack, the interrupted blood flow can result in the heart muscle being damaged or destroyed. People with angina, however, are at higher risk of having a heart attack. There are two main types of angina: Stable angina: pain lasting 5-15 minutes that is relieved by angina medication. It usually has a trigger, such as physical exercise or exertion, anxiety or emotional stress, cold temperatures, or heavy meals. Unstable angina: pain lasting longer than 15 minutes that may not be fully relieved by angina medication. It may indicate that you are having a heart attack. Unstable angina often occurs without a specific trigger. Angina symptoms are not always present because during times of low oxygen demand, e.g. when at rest, the heart muscle can function on the reduced amount of blood flow without triggering symptoms. However, when heart doesn’t get enough oxygen (e.g. during exercise) angina symptoms are triggered. Tests are available to help confirm a diagnosis of angina. These include: electrocardiogram (ECG), exercise stress test, echocardiogram, chest x-ray, coronary angiography and computerised tomography (CT) scan and magnetic resonance imaging (MRI) which can show if the heart is enlarged or the coronary arteries are narrowed. To reduce the frequency and severity of your angina symptoms and improve general heart health over time, a range of options may be recommended, from self-management and lifestyle changes to medications, and in some cases surgery.
""Angina Pectoris- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Angina Pectoris pipeline landscape is provided which includes the disease overview and Angina Pectoris treatment guidelines. The assessment part of the report embraces, in depth Angina Pectoris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angina Pectoris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Angina Pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angina Pectoris Emerging Drugs
Further product details are provided in the report……..
Angina Pectoris: Therapeutic Assessment
This segment of the report provides insights about the different Angina Pectoris drugs segregated based on following parameters that define the scope of the report, such as:
Angina Pectoris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angina Pectoris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina Pectoris drugs.
Angina Pectoris Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Angina Pectoris: Overview
Angina is chest discomfort or pain caused by reduced blood flow to the heart muscle. Treatment primarily involves relieving symptoms by resting and using angina medications, as well as lifestyle changes to improve overall heart health. Angina, which is also known as angina pectoris, occurs when the flow of blood through the coronary arteries to the heart muscle is insufficient to meet the heart’s oxygen demands, such as during physical activity.Coronary heart disease is the most common cause of reduced blood flow to the heart in people with angina. Coronary heart disease is the build-up of fatty deposits on the inside of the coronary arteries causing them to become narrow and restricting the amount of blood flowing to the heart muscle. Angina differs from a heart attack because the reduction in blood flow to the heart muscle is only temporary and does not result in damage to the heart muscle. During a heart attack, the interrupted blood flow can result in the heart muscle being damaged or destroyed. People with angina, however, are at higher risk of having a heart attack. There are two main types of angina: Stable angina: pain lasting 5-15 minutes that is relieved by angina medication. It usually has a trigger, such as physical exercise or exertion, anxiety or emotional stress, cold temperatures, or heavy meals. Unstable angina: pain lasting longer than 15 minutes that may not be fully relieved by angina medication. It may indicate that you are having a heart attack. Unstable angina often occurs without a specific trigger. Angina symptoms are not always present because during times of low oxygen demand, e.g. when at rest, the heart muscle can function on the reduced amount of blood flow without triggering symptoms. However, when heart doesn’t get enough oxygen (e.g. during exercise) angina symptoms are triggered. Tests are available to help confirm a diagnosis of angina. These include: electrocardiogram (ECG), exercise stress test, echocardiogram, chest x-ray, coronary angiography and computerised tomography (CT) scan and magnetic resonance imaging (MRI) which can show if the heart is enlarged or the coronary arteries are narrowed. To reduce the frequency and severity of your angina symptoms and improve general heart health over time, a range of options may be recommended, from self-management and lifestyle changes to medications, and in some cases surgery.
""Angina Pectoris- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Angina Pectoris pipeline landscape is provided which includes the disease overview and Angina Pectoris treatment guidelines. The assessment part of the report embraces, in depth Angina Pectoris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angina Pectoris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Angina Pectoris R&D. The therapies under development are focused on novel approaches to treat/improve Angina Pectoris.
This segment of the Angina Pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angina Pectoris Emerging Drugs
- CLBS14: Caladrius Biosciences
- IMB-101: Imbria Pharmaceuticals
- XC001: Xylocor Therapeutics
- CKD385: Chong Kun Dang
Further product details are provided in the report……..
Angina Pectoris: Therapeutic Assessment
This segment of the report provides insights about the different Angina Pectoris drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Angina Pectoris
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Angina Pectoris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angina Pectoris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina Pectoris drugs.
Angina Pectoris Report Insights
- Angina Pectoris Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Angina Pectoris drugs?
- How many Angina Pectoris drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angina Pectoris?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angina Pectoris therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Angina Pectoris and their status?
- What are the key designations that have been granted to the emerging drugs?
- Abbott Laboratories
- Astra Zeneca
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Allergan
- GlaxoSmithKline
- Novartis AG
- Pfizer
- Sanofi
- Xylocor Therapeutics
- Imbria Pharmaceuticals
- Chong Kun Dang
- Caladrius Biosciences
- XC-001
- IMB-101
- CKD385
- CLBS14
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Angina Pectoris: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Angina Pectoris– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- CLBS14: Caladrius Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- IMB-101: Imbria Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CKD385: Chong Kun Dang
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Angina Pectoris Key Companies
- Angina Pectoris Key Products
- Angina Pectoris- Unmet Needs
- Angina Pectoris- Market Drivers and Barriers
- Angina Pectoris- Future Perspectives and Conclusion
- Angina Pectoris Analyst Views
- Angina Pectoris Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.